Survival Outcomes Improve With TIL Presence in TNBC
An increased TIL count in the breast tissue was associated with improved distant recurrence-free survival in patients with triple-negative breast cancer.
Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care
Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.
Durvalumab Combo Yields OS Benefit in Advanced Biliary Tract Cancer
The phase 3 TOPAZ-1 trial of durvalumab plus chemotherapy showed a significant benefit vs chemotherapy alone for patients with advanced biliary tract cancer.
Finding Ways to Break the Mold in GU Oncology
Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.
Updates in Breast Cancer Care From the 41st Annual Miami Breast Cancer Conference
Several presentations from the 41st Annual Miami Breast Cancer Conference focused on new and evolving data in the space, according to Neil M. Iyengar, MD.
STARGLO Trial Meets OS End Point With Glofitamab in Relapsed/Refractory DLBCL
Additional data and results from the phase 3 STARGLO trial of glofitamab for patients with relapsed/refractory diffuse large B-cell lymphoma will be presented at an upcoming medical meeting.